House Panel May Subpoena FDA Investigators To Address Ketek Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency foot-dragging over questions regarding approval of the Sanofi-Aventis antibiotic leads House Energy and Commerce subcommittee to consider forcing testimony.
You may also be interested in...
House Subpoenas FDA Staffers In Ketek Investigation
Von Eschenbach’s congressional briefing documents also subpoenaed as panel delves into when FDA and Sanofi-Aventis became aware of flawed safety study.
House Subpoenas FDA Staffers In Ketek Investigation
Von Eschenbach’s congressional briefing documents also subpoenaed as panel delves into when FDA and Sanofi-Aventis became aware of flawed safety study.
Sanofi-Aventis Failed To Act Against Ketek Clinical Investigator, FDA Charges
Sanofi-Aventis tells “The Pink Sheet” DAILY that it has cooperated with FDA on the investigation and will respond to the agency warning letter within 15 days.